Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios Gouglas

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Plos One|February 11, 2021
Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysisDimitrios Gouglas, Kevin Marsh
Vaccine|July 20, 2016
Gavi's policy steers country ownership and self-financing of immunizationKlara Henderson, Dimitrios Gouglas, Laura Craw
Journal of Health Economics|July 22, 2023
An optimal mechanism to fund the development of vaccines against emerging epidemicsChristopher M Snyder, Kendall Hoyt, Dimitrios Gouglas
Epidemiologic Reviews|November 2, 2019
CEPI: Driving Progress Toward Epidemic Preparedness and ResponseDimitrios Gouglas, Mario Christodoulou, Stanley A Plotkin, et al.
Current Opinion in Virology|September 1, 2019
A review of Lassa fever vaccine candidatesKolawole Salami, Dimitrios Gouglas, Connie Schmaljohn, et al.
Health Affairs (Project Hope)|July 24, 2020
Designing Pull Funding For A COVID-19 VaccineChristopher M Snyder, Kendall Hoyt, Dimitrios Gouglas, et al.
The New England Journal of Medicine|January 19, 2017
New Vaccines against Epidemic Infectious DiseasesJohn-Arne Røttingen, Dimitrios Gouglas, Mark Feinberg, et al.
The Lancet. Global Health|October 22, 2018
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation studyDimitrios Gouglas, Tung Thanh Le, Klara Henderson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Plos One|February 11, 2021
Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysisDimitrios Gouglas, Kevin Marsh
Vaccine|July 20, 2016
Gavi's policy steers country ownership and self-financing of immunizationKlara Henderson, Dimitrios Gouglas, Laura Craw
Journal of Health Economics|July 22, 2023
An optimal mechanism to fund the development of vaccines against emerging epidemicsChristopher M Snyder, Kendall Hoyt, Dimitrios Gouglas
Epidemiologic Reviews|November 2, 2019
CEPI: Driving Progress Toward Epidemic Preparedness and ResponseDimitrios Gouglas, Mario Christodoulou, Stanley A Plotkin, et al.
Current Opinion in Virology|September 1, 2019
A review of Lassa fever vaccine candidatesKolawole Salami, Dimitrios Gouglas, Connie Schmaljohn, et al.
Health Affairs (Project Hope)|July 24, 2020
Designing Pull Funding For A COVID-19 VaccineChristopher M Snyder, Kendall Hoyt, Dimitrios Gouglas, et al.
The New England Journal of Medicine|January 19, 2017
New Vaccines against Epidemic Infectious DiseasesJohn-Arne Røttingen, Dimitrios Gouglas, Mark Feinberg, et al.
The Lancet. Global Health|October 22, 2018
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation studyDimitrios Gouglas, Tung Thanh Le, Klara Henderson, et al.
Pageof 1